Adverse events (reported; mild, no withdrawals) · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
1 finding from 1 review
Rossi et al 1983 (prazepam) reported adverse effects. Per the review's Adverse effects of interventions section: 'All but one study (Lobo et al 2004) reported adverse effects. Most of the reported adverse effects were…
1 study · 83 participants
GRADE not reported
Adverse events related to taking of blood samples · children aged 6 to 12 years
1 finding from 1 review
Intervention not reported
Adverse events (N)
The intervention showed no clear difference in adverse events (N) (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
1 finding from 1 review
Withdrawals due to adverse events · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
1 finding from 1 review
Four of the participants withdrew from the study by Kimos et al 2007 due to adverse effects, but neither the type of adverse effect nor the trial group was specified.
1 study · 44 participants
GRADE not reported
Withdrawals due to adverse events · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
1 finding from 1 review
Withdrawals due to adverse events · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
1 finding from 1 review
Harms: adverse events (poorly assessed and reported) · adults with ADHD (available evidence for participants aged between 25 to 53 years old)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Harms: adverse events (poorly assessed and reported) · adults with ADHD (available evidence for participants aged between 25 to 53 years old)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse events (number of adverse events/person/year) · adults (> 18 years of age) with either COPD or recurrent acute exacerbations of chronic bronchitis
The intervention showed no clear difference in adverse events (number of adverse events/person/year) (low certainty).
1 finding from 1 review
Proportion of participants experiencing adverse events · Patients with acute low‐back pain
It is very uncertain whether NSAIDs changes proportion of participants experiencing adverse events compared with placebo (very low certainty).
1 finding from 1 review
Proportion of participants experiencing adverse events · Patients with acute low‐back pain
It is very uncertain whether selective COX‐2 inhibitors changes proportion of participants experiencing adverse events compared with non‐selective NSAIDs (very low certainty).
1 finding from 1 review
Participants with at least some Side Effects · community‐dwelling older adults ≥ 65 years of age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participants with adverse events ‐ death Clinical criteria · healthy older adults aged ≥ 60 years
Recombinant zoster vaccine showed no clear difference in participants with adverse events ‐ deathClinical criteria compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects requiring withdrawal/discontinuation of study medication · People on continuous VKA treatment undergoing minor oral surgery or dental extractions (eligibility included DOACs and all ages; all four…
Antifibrinolytic therapy - locally-applied tranexamic acid (TXA)… showed no clear difference in side effects or other adverse events requiring withdrawal compared with placebo (placebo solution/mouthwash) (moderate certainty).
1 finding from 1 review
Safety of sealants and fluoride varnishes (adverse events) · Children and adolescents (general population, aged under 20 years)
1 finding from 1 review
Intervention not reported
Adverse events none of the studies reported on this outcome · children and adolescents aged 4 years to 18 years, with chronic musculoskeletal pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse events none of the studies reported on this outcome · children and adolescents aged 4 years to 18 years, with chronic musculoskeletal pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse events none of the studies reported on this outcome · children and adolescents aged 4 years to 18 years, with chronic musculoskeletal pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: Clinically important specific adverse events · People with serious mental illness (all included participants had schizophrenia); majority aged 18 to 65 years per NIMH 1987, or with…
The review found no eligible studies for this question.
1 finding from 1 review